



NWR Health Conference Presentation

March 2026



Important Notice & Disclaimer

This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this presentation are made only as at the date of this presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes of giving you summary information and background about the Company and its activities, current as at 20 March 2025, and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in the Company.

No liability

To the maximum extent permitted by law, the Company, or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees, agents and advisers (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, the Company, or the Company's securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Eligible recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice.

This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States.

The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Confidentiality

This presentation is confidential and not for further distribution. It is provided by the Company on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation.

Important Notice & Disclaimer (cont.)

Not financial product advice

Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not financial product or investment advice or a recommendation to acquire the Company's securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own research of the Company and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Past performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as an indication of (and gives no guidance as to) future performance.

Future performance

This presentation contains certain forward-looking statements (including financial forecasts) with respect to the financial condition, operations and business of the Company and certain plans and objectives of the management of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company and its respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Financial data

All figures in the presentation are Australian dollars (\$) or A\$) unless stated otherwise. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Financial Information

The pro forma financial information provided in this presentation is for illustrative purposes only and does not represent a forecast or expectation as to the Company's future financial condition and/or performance. This document has been prepared at a time where the review of financial information contained in this presentation has not been completed and accordingly, you should only rely on any expectation as to the Company's future financial condition and/or performance that is contained in a prospectus or other offering document which may be issued by the Company in connection with any offer of the Company's securities.

Acknowledgement

Persons who access, receive, review or attend this presentation are required to inform themselves of, and comply with, all of the above restrictions and prohibitions and none of the Company or the Related Parties accepts any liability to any person in relation thereto. This presentation is made to you on the basis that by attending, accessing or receiving or reviewing this presentation, you confirm that you understand and agree to the contents of this important notice and disclaimer and that you are a person to whom this presentation may lawfully be made in accordance with laws applicable to you, including those of the jurisdiction in which you are located.

What is cryopreservation?

The science of preserving biological materials at ultra-low temperatures that underpins many areas of the healthcare system.

Our priority markets are:

- Cell & gene therapies.
- Blood products.
- Animal and aquaculture reproduction.



Built for 1960s Science

Cryopreservation is breaking under 21st-century demand

Isolated Technology: Stand-alone cryopreservation unit is the current gold standard.

No intelligence or insight: Data capture and analytics to support GMP compliance and FDA approvals uncommon.

Damaging: use of liquid nitrogen and harmful toxins mandatory throughout process.

Expensive: hidden costs and impacts on the sample costing users time, quality and money.



Cryopreservation is broken.

- US blood supply has experienced repeated declared shortage events since 2020.
- Scaling cryopreservation manufacturing is the cell & gene sector's most cited hurdle.
- 60% of cell and gene therapy manufacturers are running default freeze profiles that are not optimised for their cell type.
- Most manufacturers release batches without freeze curve data, removing the only early warning signal for process failure.



A scientist wearing a white lab coat, safety glasses, and blue gloves is working with a cryopreservation machine. The machine is white and has a large flat top surface. The scientist is adjusting a component of the machine. The background is a plain, light-colored wall.


Vitrafy Life Sciences (ASX: VFY) is building a cryopreservation ecosystem that digitises, optimises, and decentralises the preservation and transport of biological materials.

vitrafy^o

Vitrafy cryopreservation ecosystem delivers customer value at the solution level.



Guardion Cryopreservation Freezer Unit




LifeChain Software Orchestration Platform

vitrafy
LIFE SCIENCES

Vitrafy Thawing Units



Vitrafy Smart Consumables



- **Connected:** end-to-end ecosystem connection.
- **Intelligent:** Data capture and analytics empowering intelligent decision making.
- **Quality:** every step designed to preserve medical grade quality and hygiene.
- **Value Generative:** hidden savings and improved performance, saving time, improving quality and providing a better post thaw product – ultimately, preserving life.

Guardion Hardware

Legacy Hardware

- ▼ Manual, operator dependent
- ▼ Limited intelligence
- ▼ Limited throughput
- ▼ Slow and inconsistent freeze cycles (hours)
- ▼ Energy Inefficient
- ▼ Use of unsafe materials such as liquid nitrogen (LN2)
- ▼ Limited portability



Vitrafy Guardion

- ✔ Controlled & tailored cryopreservation
- ✔ Automated & Intelligence
- ✔ Continuous Throughput
- ✔ Rapid processing times <5 min
- ✔ Low Power requirement
- ✔ Liquid Nitrogen Free
- ✔ Integration with LifeChain™

Controlled | Intelligent | LN2 Free

LifeChain Software


LifeChain delivers quality control across the pre-clinical, clinical and commercial supply chain to support GMP compliance and FDA submission data sets.

Standardisation: Facilitates the standardisation of quality outcomes ensuring consistency across multiple sites.

Auditability: Chain of command functionality ensures workflows are traceable.

Digitisation: Digitising paper workflows to create a single, central source of truth.


Connectivity: IoT connectivity allowing third-party device outcomes to be monitored via the ecosystem.



The screenshot shows the 'Workflows' section of the LifeChain software. It displays a table with columns for Name, Current Activity, Progress, Assignee, Updated, and Duration. The table lists 11 tasks, all assigned to Andrew Wyan, with a duration of 2 hours and 21 minutes. The progress for all tasks is 0%.

Name	Current Activity	Progress	Assignee	Updated	Duration
#1002 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1003 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1004 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1005 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1006 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1007 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1008 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1009 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1010 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1011 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes

vitrafy
lifechain




The screenshot shows the details of a workflow for 'Human Platelet 27112501'. It displays a sequence of steps: 1. Collection, 2. Preparation, 2.1 Baseline Testing of Sample, 2.2 Transfer Sample into Packaging, 2.3 Add CP-950 to Sample, 2.4 Centrifuge Sample, 2.5 Remove Supernatant from Sample, 2.6 Prepare for freezing, 3. Cryopreservation, 4. Storage, and 5. Thawing. Each step is accompanied by a dropdown menu and a list of parameters with their values.

Step	Activity	Parameters
1	Collection	
2	Preparation	
2.1	Baseline Testing of Sample	
2.2	Transfer Sample into Packaging	Selected Dia Type: Cryopore 200
2.3	Add CP-950 to Sample	Part Code: C0250
2.4	Centrifuge Sample	WRF: 3000, 127
2.5	Remove Supernatant from Sample	Length (mm): 27.7
2.6	Prepare for freezing	Min Volume (mL): 50
3	Cryopreservation	Max Volume (mL): 20
4	Storage	
5	Thawing	

*By preserving sample quality with consistency, the **Vitrafy ecosystem** unlocks better products and better care when it matters most.*



One Solution, Multiple Go-to-Market Applications



Animal Reproduction


Vitrafy's cryopreservation ecosystem has broad applicability across biological materials.

Global Scale

Critical for food availability

Commercial Agreement in place

Globally, >2,200 collection sites across aquaculture, bovine and porcine.




Blood & Blood Products

Why

Critical & growing **need**
Global Scale

~ 8,000 points (collection, manufacturing, storage and points-of-care) across the blood cryopreservation supply chain that underpin blood and cell & gene therapy products.



Cell & Gene Therapies

Rapid **growth**
Needs solutions
Global Scale


Commercial Progress

With clear pathway to commercial adoption across our target markets.

Clear strategic pillar for Animal Health commercialisation with a global leader.



Established US Operations with experienced, in country leadership.



Second-generation Guardian freezer unit launched in the US.

Successfully completed Phase 1 studies on Blood Platelets with US Army with outstanding results



Developing product manufacturing capability to meet commercial demand

Outlook

- Expand and convert new & existing customer pipeline opportunities in Human Health;
- Successfully complete the phase II studies with the USAISR;
- Commencing work under the agreement with IMV Technologies and scaling existing aquaculture clients;
- Commencing and securing medical device registration to expand the addressable market in the U.S.
- Building manufacturing capacity in the US and a supply of devices in advance of market demand.



Follow our progress



[linkedin.com/company/vitrafy-life-sciences](https://www.linkedin.com/company/vitrafy-life-sciences)



[vitrafy.com](https://www.vitrafy.com)



[VFY.ASX](https://www.vfy.asx)

